MedTrace Logo

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

NCT04730258 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-05-18

No results posted yet for this study

Summary

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

Conditions

Interventions

DRUG

CFI-400945

The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.

DRUG

Azacitidine

Azacitidine will be given at its labeled dose and schedule

Sponsors & Collaborators

  • Treadwell Therapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • Gautam Borthakur, MD · The University of Texas MD Anderson Cancer Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-16
Primary Completion
2026-01-31
Completion
2026-01-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04730258 on ClinicalTrials.gov